Results 11 to 20 of about 854 (146)

Identifying Factors Associated With the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice [PDF]

Neurology International
Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing
Yoshitaka Nagashima, Yusuke Nishimura, Ryuta Saito   +2 more
exaly   +5 more sources

Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks After Unsuccessful Treatment With a Triptan [PDF]

Neurology International
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50% at 1
Yasushi Shibata, Yoichi Harada
exaly   +5 more sources

The Potential of Lasmiditan in Migraine. [PDF]

Therapeutic Advances in Neurological Disorders, 2020
Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT 1F ) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties.
Margarita Sánchez-Del-Río, Bianca Raffaelli, Jasper Mecklenburg   +2 more
exaly   +3 more sources

Serotonin Syndrome in the Acute Treatment Landscape of Migraine: The Lasmiditan Experience [PDF]

Frontiers in Neurology, 2023
BackgroundSerotonin syndrome (SS) symptoms overlap with adverse events associated with lasmiditan, a 5-HT (serotonin)1F receptor agonist for acute treatment of migraine.
Maurice Borges Vincent, Stewart J Tepper, Rashna Khanna   +2 more
exaly   +4 more sources

Integrative snRNA‐seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease [PDF]

Clinical and Translational Medicine
Background Alzheimer's disease (AD) is a growing healthcare crisis with limited effective therapies. This study aims to identify new candidate drugs that can be repurposed using key transcriptional regulators (DERs) in AD as therapeutic targets.
Martin Nwadiugwu, Md Selim Reza, Boluwatife Afolabi, Demetrius M. Maraganore, Hui Shen, Hongwen Deng   +5 more
doaj   +3 more sources

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis [PDF]

The Journal of Headache and Pain
Background Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data.
Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, Duangnapa Roongpiboonsopit, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong   +7 more
doaj   +3 more sources

Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study) [PDF]

Therapeutic Advances in Neurological Disorders
Background: Lasmiditan, an oral 5-HT 1F receptor agonist, has been recently approved for acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, scarce data is available regarding effectiveness and tolerability in the ...
Gloria Vaghi, Luigi Francesco Iannone, Michele Corrado, Federico De Santis, Marina Romozzi, Gabriele Sebastianelli, Giorgio Dalla Volta, Marco Bolchini, Andrea Burgalassi, Francesco De Cesaris, Maria Albanese, Nicola Mercuri Biagio, Raffaele Ornello, Simona Sacco, Francesca Pistoia, Gennaro Saporito, Francesco Casillo, Gianluca Avino, Antonio Granato, Antonio Russo, Marcello Silvestro, Catello Vollono, Michele Trimboli, Alberto Doretti, Mariarosaria Valente, Sabina Cevoli, Edoardo Mampreso, Cristina Tassorelli, Roberto De Icco   +28 more
doaj   +2 more sources

Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series [PDF]

Brain Sciences
Background: Triptans and lasmiditan are considered specific acute medications for migraine attacks. Despite the efficacy of these treatments, continuation of these medications is limited because some patients experience adverse effects.
Yasushi Shibata
doaj   +2 more sources

Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription [PDF]

Therapeutic Advances in Neurological Disorders
Background: Migraine is a highly prevalent neurological disorder and a leading cause of disability worldwide. Although triptans and non-steroidal anti-inflammatory drugs are widely used, a substantial proportion of patients show inadequate responses ...
Masahito Katsuki, Yuya Yamada, Taisuke Ichihara, Yasuhiko Matsumori   +3 more
doaj   +2 more sources

Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan [PDF]

Neurology and Therapy
Introduction Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities.
Naoko Sanno, Kevin Y. Urayama, Joji Mori, Kenichi Yoshizawa, Chie Hashimoto   +4 more
doaj   +2 more sources